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Abstract
Background: Solitary fibrous tumor of the pleura (SFTP) is an uncommon neoplasm arising from mesenchymal
cells. The aim of this study is to summarize the experience and the outcome of the surgical treatment for 39 cases
of SFTP.
Methods: From January 2004 to December 2008, 39 patients underwent surgical resection of SFTP in our
department. All patients had clinical follow-up by the same team of surgeons. The mean follow-up was 40.3
months.
Results: A local removal of the neoplasm was accomplished by video-assisted thoracic surgery (VATS) in 9 patients
(group A) and by thoracotomy in 30 patients (group B) respectively. Comparing with group B, operations in group
A took significantly less operative time, blood loss and spent less time in the intensive care unit and hospital. All
specimens were positive for CD34 and Bcl-2. One patient developed recurrence, and the remaining 38 patients are
alive and disease free at the end of follow-up.
Conclusions: Malignant SFTP still had the potential recurrence. VATS represents the more acceptable choice for
the selected patients with SFTP.
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Background
As a rare primary neoplasm arising from mesenchymal
cells in the areolar tissue subjacent to the mesothelial-
lined pleura, the solitary fibrous tumor of the pleura
(SFTP) was first mentioned by Wagner in 1870 [1], and
the pathologic description did not appear until 1931 [2].
Due to the rarity of SFTP, there were only fewer than
800 cases reported before 2002 [3], and the understand-
ing of this disease still remains unclear. Moreover, con-
troversy about the origin of this uncommon tumor led
to a variety of terms applied to the tumor in earlier
years, such as localized pleural mesothelioma, pleural
fibroma, localized fibrous mesothelioma, submesothelial
fibroma, and localized fibrous tumor [3].
SFTP is a mesenchymal tumor that tends to involve
the pleura, although it has also been described in other
thoracic areas (mediastinum, pericardium and pulmon-
ary parenchyma) and in extrathoracic sites (meninges,
epiglottis, salivary glands, thyroid, kidneys and breast)
[3,4]. SFTP usually presents as a peripheral mass abut-
ting the pleural surface, to which it is attached by a
broad base or, more frequently, by a pedicle that allows
it to be mobile within the pleural cavity [3,5,6]. Unlike
mesothelioma, SFTP is not asbestos-related and is
usually a benign, rarely aggressive tumor, although a
small percentage of patients may develop locoregional
recurrence [3,7,8].
Due to the unclear biological characteristics, accurate
prediction for the clinical course of patients with SFTP
still remains difficult. Herein we analyzed a consecutive
series of 39 patients with SFTP who underwent surgical
resection in our department, and assessed the effective-
ness and necessity of surgical therapy administered in
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Material and methods
Patients
From January 2004 to December 2008, a retrospective
analysis was carried out of 39 patients who underwent
resection of SFTP at our department. Preoperative eva-
luation included bronchofibroscope and chest computed
tomography (CT) scan. All these patients didn’t received
preoperative chemoradiotherapy. The information about
the age and gender of patients, course of disease, initial
manifestations or symptoms, history of tobacco con-
sumption, location and size of the lesions, surgical com-
plication and outcome was recorded (table 1). The
histological diagnosis was obtained postoperatively from
the resected specimen. Postoperative death was defined
as death within 30 days after surgery or before discharge
from the hospital. To reconfirm the diagnosis of SFTP,
the same pathologist reviewed all available histological
slides. Following histological review, all slides were re-
classified as benign or malignant according to the fol-
lowing criteria: high cellularity, presence of nuclear aty-
pia, mitotic count of more than four mitoses per ten
high-power fields (HPF), and presence of necrosis [9].
All patients had clinical follow-up by the same team of
surgeons. Stable clinical outcome was also confirmed by
telephoning the patients. The mean follow-up was 40.3
months (range: 30~89 months).
Surgical technique
All operations were performed under two-lumens intuba-
tion and general endotracheal anesthesia. VATS is per-
formed in the case of small and pedunculated lesions.
For bulky tumor with diameter greater than 5.0 cm or
SFTP with a large broad base of attachment at the parie-
tal pleura, thoracotomy is mandatory to achieve radicality
in resection. In our series, there were 30 cases with
tumor greater than 5.0 cm underwent thoracotomy and
accquired integrated excision. A local removal of the
neoplasm was accomplished by VATS in 9 patients
(group A) and by thoracotomy in 30 patients (group B)
respectively. No patient underwent aggressive pneumo-
nectomy. For obtaining histologic negative margins, fast
frozen section in operation was performed. For 9 patients
with tumor of 5.0 cm diameter or smaller, surgical resec-
tion was performed under video-assisted thoracic surgery
(VATS). At the end of the videothoracoscopic procedure,
the tumor was put in a retrieval bag and a small incision
was performed, then the tumor was pulled away.
Immunohistochemistry
Immunohistochemistry was performed on 4-μm-thick
paraffin sections using the Envision TM detection system
(DakoCytomation, Carpinteria, CA) and according to the
manufacturer’s recommendations. The following primary
antibodies were used: Mouse monoclonal antibodies for
CD34 (clone QBEnd/10, working dilution, Maixin Bio-
tech, China), Ki67 (clone MIB-1, 1:200, Dako) and Bcl-2
(clone 8C8, working dilution, Maixin Biotech, China).
Negative controls were performed for each case by repla-
cing primary antibody with mouse IgG. For Ki-67, Sec-
tions from colon adenocarcinoma were used as positive
controls. For Bcl-2 and CD34, tumor infiltrating lympho-
cytes and vascular endothelial cells served as internal
positive controls respectively. As for Ki-67, the positive
cells in five maximally labeled high power fields were
counted, and the labeling index (LI) was expressed as the
percentage of the labeled tumor cells.
Statistical methods
The data are expressed as the mean ± SEM. The differ-
ence between means was performed with ANOVA. All
Table 1 Clinicopathological characteristics of 39 patients
with SFTP





< 40 5 12.8
40~60 28 71.8
> 60 6 15.4
Clinical presentation















< 5.0 9 23.1
5.0~10.0 23 59.0
> 10.0 7 17.9
Total 39 100
There was significant difference in sex ratio between male and female
patients, and significance can be also observed in different age group. No
significant difference in the location of lesion could be observed between the
right and left thoracx.
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ware (Chicago, IL, USA) and p < 0.05 was considered as
statistically significant.
Results
During the 5 years from 2004 to 2008, the cases with
SFTP in our hospital were observed gradually increased
per year (Figure 1A). Comparing to the simultaneous
total number of operations, the ratio also shows an
increasing tendency (Figure 1B). In our series, 27
(69.2%) patients were female and the sex ratio (female/
male) was 2.25/1. The mean age at surgery was 44.6 ±
14.5 years (range: 22~77 years). Twenty-eight of these
patients (71.8%) were between 40~60 years and only 5
patients (12.8%) were under 40 (table 1). And SFTP
occurred most frequently in patients aged from 40 to 60
years in our series. The course of disease ranged from
0.5 month to 6 years (mean of 1.56 years). Twenty
(51.3%) of our patients had symptoms such as coughing,
expectoration and chest pain. In these 20 patients,
achropachy was encountered in 4 cases (10.3%), pyrexia
in 3 (7.7%). One (2.6%) obstructive pneumonia due to
obstruction of the bronchus was encountered. And
hypoglycemia was not observed in our series. The
remaining 19 patients (48.7%) were asymptomatic at the
time of diagnosis (table 1). Two patients had multiple
hepatic cysts and one had the history of thoracic injury.
No concomitant malignant lesion was encountered.
To exclude other lessions arising from bronchus,
bronchoscopic studies were performed in fifteen patients
(38.5%). Twelve patients (30.8%) underwent preoperative
CT-guided fine needle aspiration biopsy (FNAB). Only
two specimens (16.7%) revealed benign appearing spin-
dle cells and this suggested diagnosis of benign pleural
fibrous tumor. The remaining ten cases (83.3%) speci-
mens were not significant. Chest radiographs and CT
scan examination were performed preoperatively in all
cases. Chest radiographs of SFTP usually demonstrated
a sharply marginated globular mass. Mostly, the mani-
festation of CT scan was a smoothly marginated, ellipti-
cal, abnormal mass in the thorax. The lesion has a
density greater than simple fluid and with partial
enhancement occasionally (Figure 2). Positron emission
tomography (PET) scanning was performed in 2 cases,
and the tumors had no fluorodeoxyglucose (FDG)
uptake (SUV 2.1 and 1.0 respectively).
Twenty-four tumors (61.5%) arose from the visceral
pleura and 15 (38.5%) from the parietal pleura, sixteen
(41.0%) were pedunculated and 23 (59.0%) presented a
broad base of attachment. Among tumors arising from
the visceral pleura, two showed a prevalent intrapul-
monary growth (the so-called inverted fibroma). All
tumors arising from the parietal pleura were broad
based and not pedunculated. The mean maximum dia-
meter of tumors was 7.71 ± 4.78 cm (range: 2.0 to 22.0
cm). Most of the SFTPs in our series (59.0%) had the
maximum diameter ranged from 5.0 to 10.0 cm. Nine of
them (23.1%) were under 5.0 cm and 7 (17.9%) over
10.0 cm (table 1). The smallest tumor was 2.0 cm in
greatest diameter and the largest was 22.0 × 19.0 × 19.0
cm. No synchronous SFTP or associated malignant dis-
ease was observed in our series.
Thirty patients underwent surgery by standard thora-
cotomy (group B). And VATS was performed in 9
patients (group A). Of these 9 underwent VATS, tumor
resection with negative incision margin were performed
and none required a conversion to open thoracotomy.
Four wedge resections were performed for tumors
related to the visceral pleura (group A). And two SFTPs
located centrally in the lobe required lobectomy due to
intraparenchimal extension of the tumor (inverted
fibroma). No patient suffered from more aggressive
pneumonectomy or chest-wall resection in our series.
The patients’ data are also given in table 2. Comparing
with thoracotomy group, operations in group A took
significantly less time and blood loss (114.78 ± 30.04
min and 133.33 ± 79.06 ml respectively). Althrough
there was not significantly difference, the VATS group
had fewer requirements for transfusion during the
admission. As for the length of hospital stay, the VATS
group spent less time in the intensive care unit and hos-
pital compared with the thoracotomy approaches. The
overall complication rate was not different for each
group. This number includes two cases of postoperative
Figure 1 Gradually increasing tendency of SFTPs. (A) During the 5 years from 2004 to 2008, the cases with pathological diagnosis of SFTP in
our hospital were observed gradually increased. (B) Comparing to the simultaneous total number of operations, the ratio is also in increasing.
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substantive impact on overall recovery. The incidence of
respiratory infections was not different for two groups
n o rw a st h en e e dt or e t u r nt ot h ei n t e n s i v ec a r eu n i t
with respiratory compromise. The operative mortality
was not observed in both groups.
According to the criteria of England et al [9], 35 cases
(89.7%) in our series were classified as benign and 4
cases (10.3%) were found to be malignant. All specimens
were positive for CD34 (which helps to differentiate SFT
from mesothelioma [10]). And all cases were also posi-
tive for Bcl-2. Ki-67 LI ranged from 2% to 10% and 15%
to 30% in benign and malignant SFTPs respectively (Fig-
ure 3).
Follow-up continued until June 2011, ensuring a mini-
mal follow-up of 30 months. Thirty-eight patients sub-
mitted the regular follow-up program that included
clinical examination and chest roentgenogram after 1
month and every 3 months. Chest CT scan was per-
formed every 6 months. Local recurrence at a thoraco-
scopic site was not observed in our series. One patient
with malignant SFTP underwent wedge resection by
VATS lost during follow-up. In operation, the histologic
negative margin was obtained. However, CT scan
showed another smoothly marginated abnormal mass
o c c u r r e da tr i g h tt h o r a x( F i g u r e4 )w h e nh ec a m eb a c k
6 months after surgery. FNAB revealed spindle cells and
thus suggested the recurrence of SFTP. This patient
refused further treatment and lost touch again after dis-
charging. The remaining 38 patients were submitted a
mean follow-up of 40.3 months (range: 30~89 months).
At the end of follow-up, none of these patients died,
and the concomitant malignant lesion was not found in
our series after operation.
Discussion
According to the review by de Perrot et al [3], approxi-
mately 800 cases of SFTP have been reported in the lit-
erature before 2002 July. After carefully searching the
subsequent literatures, the author observed that there
were additional 760 cases of SFTP reported in the last 7
years. The increasing occurence of SFTP might owe to
the advancement of methods for diagnosis, especially by
the aids of immunohistochemistry and electronmicro-
scope. Meanwhile, this phenomenon making us
hypothesesed that the incidence of SFTP seems to be
increasing, and the results from our series also sup-
ported this viewpoint. An accredited hypothesis about
the aetiopathogenesis of SFTP is that these tumors ori-
ginate from submesothelial stromal cells with fibroblas-
tic or myofibroblastic phenotype, whose growth is
promoted by an aberrant reaction to inflammatory or
hormonal stimuli [11].
By the aids of imageological examination, SFTP is
relatively easy to diagnose when located in typical sites
[12]. Rarely, diagnosis of SFTP may prove more challen-
ging when the lesion is located in an unusual site. The
clinical value of biopsy before excision is still controver-
sial. Scarsbrook and his colleagues recounted an alarm-
ing case in which a solitary fibrous pleural tumor
recurred after an ultrasoundguided transthoracic biopsy
[13]. Although there have been no other similar reports
in the literature, it seems prudent to avoid unnecessary
Table 2 Operative data of 39 patients with SFTP
Total (n = 39) Group A (n = 9) Group B (n = 30) p
Blood loss (ml) 308.97 ± 167.75 133.33 ± 79.06 361.67 ± 150.68 0.0001
Surgical time (min) 169.63 ± 50.28 114.78 ± 30.04 177.67 ± 50.81 0.0033
Transfusion (no. of patients) 5(5/39) 0(0/9) 5(5/30) 0.2284
LOS ICU (days) 2.77 ± 0.67 2.22 ± 0.44 3.20 ± 0.55 0.0006
LOS* (days) 14.26 ± 2.26 12.89 ± 2.20 14.67 ± 2.14 0.0262
Postoperative complications
Pleural effusion 2(2/39) 0 2(2/30) 0.4419
Pulmonary infection 4(4/39) 1(1/9) 4(4/30) 0.8722
LOS, length of hospital stay.
Figure 2 Enhancement of SFTP showed by chest CT scans.( A ,
B) Before the injection of contrast agent. (C, D) Partial enhancement
of SFTP after injection.
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study recommends [13], biopsy should only be done if
disease management will be substantially affected by the
results or if surgical intervention is contraindicated and
a diagnosis would alter treatment. Among the 12
patients underwent preoperative FNAB in our series,
only two cases (16.7%) specimens revealed benign
appearing spindle cells and suggested diagnosis of
benign pleural fibrous tumor. The remaining ten cases
(83.3%) specimens were not significant. The results also
demonstrated the limited assistance of preoperative
biopsy for the diagnosis of SFTP.
SFTP is usually histologically benign, but the presence
of cellular atypia, necrosis, overlapping of nucleus and a
high mitotic index (defined as being in excess of 4/10
HPF) is strongly indicative of malignancy [9]. The neo-
plastic cells are typically CD34+ and BCL2+ and are
negative for cytokeratin [14-16]. Occasionally, malignant
SFTP exhibited a negative reaction to CD34 immunos-
taining [17]. But in our series, we did not observed the
negative CD34 immunostaining even in malignant cases.
According to the report from Cardillo et al [18], the
malignant tumors were usually greater than 10 cm in
diameter. However, there were 8 cases with tumor lager
than 10 cm in our series were diagnosed as benign
SFTP and free of recurrence during follow-up. There-
fore, the author presumed that the size of tumor might
not the mandatory diagnostic criteria of malignant
SFTPs. For instance, due to lack of the chance for health
examination, patients from the region with poor medical
condition usually have the bulky tumor.
Complete surgical resection was the preferred therapy
for both benign and malignant SFTPs, and the most
important indicator of the clinical outcome in SFTP is
the complete and radical resection of the tumor [19].
Since this tumor is not a primary lung neoplasm, the
surgeon should strive to save as much lung as possible
in both the benign and malignant varieties while obtain-
ing histologic negative margins, if the tumor arises from
the visceral pleura [20]. It also stated that though ped-
unculated tumors are effectively removed using wedge
resection, sessile lesions require that a larger mass of
lung parenchyma be excised to reduce the likelihood of
recurrence. In our series, local removal was the main
choice for patients with SFTP. For tumors located in the
pulmonary parenchyma, wedge resection or lobectomy
was the preferred procedure.
Small pedunculated tumors located on the visceral
pleura can be safely removed by VATS [18,21]. And
some authors have also recommended the VATS to
obtain a more precise view of the resection margins in
some large, broad-based tumors of the parietal pleura
[18]. In our opinion, the VATS is useful in the case of
small and pedunculated lesions. For bulky tumor or
SFTP with a large broad base of attachment at the par-
ietal pleura, thoracotomy is mandatory to achieve radi-
cality in resection. To avoid potential implantation
metastasis, the tumor should be resected integratedly as
far as possible. Moreover, because of the potential
metastasis and local recurrence at the port sites, the
contact between the tumor and the thoracoscopic sites
also should to be avoided [18]. Therefore, we choosed
the pedunculated lesion with diameter smaller than 5.0
cm as the indication of VATS. Due to the malignant
Figure 4 Recurrence of SFTP in a case.( A )C Ts c a ns h o w e da
prevalent intrapulmonary growth (the so-called inverted fibroma).
(B) Another smoothly marginated abnormal mass occurred at right
thorax with pleural effusion 6 months after surgery.
Figure 3 Immunohistochemical staining of the SFTPs.( A )
Positive staining of CD34 was observed especially in the vascular
endothelial cells and tumor cells (200). (B) Positive staining for CD34
in a malignant SFTP (200). (C) Strong positive expression of Bcl-2
was observed in the cytoplasm of tumor cells (200). (D) Positive
staining of Bcl-2 in a malignant SFTP (200). (E) Ki-67 LI is about 5%
in a benign SFTP (200). (F) A malignant case in which the Ki-67 LI is
about 15% (200).
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should be avoided to reduce the possibility of local
recurrence.
Conclusion
In summary, although the complication did not present
significance between VATS and open group, the patients
underwent VATS did obtain less blood loss and opera-
tive time, as well as ICU and hospital stay. Moreover,
local recurrence at a thoracoscopic site was not
observed in patients underwent tumor resection under
VATS. These results presented that local removal by
VATS with intraoperative assessment of free surgical
margins was the recommended choice for surgical treat-
ment of selected patients with SFTP.
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